

Innate Study

Secondary Progressive Multiple Sclerosis

Introduction

Neurodegenerative Disorders Research Pty Ltd and Innate Immunotherapeutics Limited believe that secondary progressive multiple sclerosis is a type of neurodegenerative disorder, associated with a chronic immunological reaction. There are no known treatments. For this reason Neurodegenerative Disorders Research Pty Ltd has partnered with Innate Immunotherapeutics Limited to embark on a study of a potential treatment.

Aim

To assess the safety, tolerability, efficacy and pharmacodynamics of MIS416 when administered intravenously once a week over 52 weeks in patients with secondary progressive multiple sclerosis.

Hypothesis

Multiple sclerosis is a chronic immune-mediated neurological disorder where the myelin sheath surrounding nerves are attacked by the immune system causing scarring or lesions at sites in the central nervous system. MS416 removes unwanted potentially immunogenic antigens and retains select desirable immunostimulatory cytosolic and cell wall components.

Funding

Innate Immunotherapeutics Limited

Phase 2B

Randomised, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in the treatment of subjects with secondary progressive multiple sclerosis.

Criteria

To be eligible for the Innate Study participants (male or female) must have secondary progressive multiple sclerosis and be aged 18–70 years

Ethics approval

Bellberry Human Research Ethics Committee

Status

Enrolment to commence in July 2015

Principal Investigator

Professor Peter K Panegyres
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au